Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Capecitabine; Irinotecan
- Indications Breast cancer; Gastrointestinal cancer; Solid tumours
- Focus Adverse reactions
- 10 Sep 2018 Biomarkers information updated
- 22 Sep 2005 New trial record.